Cochrane Central Register of Controlled Trials (Cochrane Register of Studies Online)

1. MESH DESCRIPTOR Prediabetic state 2. MESH DESCRIPTOR Glucose Intolerance 3. (prediabet* or pre diabet*):TI,AB,KY 4. (intermediate hyperglyc?emi*):TI,AB,KY 5. ((impaired fasting ADJ2 glucose) or IFG or impaired FPG):TI,AB,KY 6. glucose intolerance:TI,AB,KY 7. ((impaired glucose ADJ (tolerance or metabolism)) or IGT):TI,AB,KY 8. ((risk or progress* or prevent* or inciden* or conversion or develop* or delay*) ADJ4 (diabetes or T2D* or NIDDM or "type 2" or "type II")):TI,AB,KY 9. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 10. MESH DESCRIPTOR Dipeptidyl‐Peptidase IV Inhibitors 11. gliptin*:TI,AB,KY 12. ((dipeptidyl peptidase or dipeptidylpeptidase or dpp) ADJ ("4" or IV) ADJ inhibitor?):TI,AB,KY 13. (alogliptin or SYR 322 or SYR322):TI,AB,KY 14. anagliptin:TI,AB,KY 15. bisegliptin:TI,AB,KY 16. (carmegliptin or R1579 or RO4876904):TI,AB,KY 17. (denagliptin or GW 823093 or GW823093):TI,AB,KY 18. (dutogliptin or PHX1149):TI,AB,KY 19. (evogliptin or DA 1229):TI,AB,KY 20. (gemigliptin or LC15 0444):TI,AB,KY 21. (gosogliptin or PF 00734200 or PF 734200):TI,AB,KY 22. (linagliptin or BI 1356 or BS 1356):TI,AB,KY 23. (melogliptin or GRC 8200):TI,AB,KY 24. (omarigliptin or MK 3102):TI,AB,KY 25. (sitagliptin or MK 0431):TI,AB,KY 26. (saxagliptin or BMS 477118):TI,AB,KY 27. (teneligliptin):TI,AB,KY 28. (trelagliptin or SYR 472):TI,AB,KY 29. (vildagliptin or LAF 237 or LAF237):TI,AB,KY 30. MESH DESCRIPTOR Glucagon‐Like Peptide 1 EXPLODE ALL TREES WITH QUALIFIERS AA,AG 31. ((glucagon like peptide* or GLP 1 or GLP1) ADJ3 (analog* or agonist*)):TI,AB,KY 32. (exenatide or AC 2993 or ITCA 650):TI,AB,KY 33. (liraglutide or NN 2211 or NN2211 or NNC 90 1170 or NNC90 1170):TI,AB,KY 34. (albiglutide or GSK 716155):TI,AB,KY 35. (elsiglutide):TI,AB,KY 36. (lixisenatide or AVE 0010):TI,AB,KY 37. (dulaglutide or LY2189265 or LY 2189265):TI,AB,KY 38. (taspoglutide or BIM 51077 or BIM51077 or ITM 077 or ITM077 or R 1583 or R1583 or RO 5073031 or RO5073031):TI,AB,KY 39. (semaglutide or NN 9535 or NN9535):TI,AB,KY 40. (teduglutide or ALX 0600 or ALX0600):TI,AB,KY 41. #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 42. #9 AND #41

MEDLINE (OvidSP)

Block 1: Prediabetes 1. Prediabetic state/ 2. Glucose Intolerance/ 3. (prediabet* or pre diabet*).tw. 4. intermediate hyperglyc?emi*.tw. 5. ((impaired fasting adj2 glucose) or IFG or impaired FPG).tw. 6. glucose intolerance.tw. 7. ((impaired glucose adj (tolerance or metabolism)) or IGT).tw. 8. ((risk or progress* or prevent* or inciden* or conversion or develop* or delay*) adj4 (diabetes or T2D* or NIDDM or "type 2" or "type II")).tw. 9. or/1‐8 Block 2: DPP‐4 inhibitors/GLP‐1 analogues 10. Dipeptidyl‐Peptidase IV Inhibitors/ 11. gliptin*.tw. 12. ((dipeptidyl peptidase or dipeptidylpeptidase or dpp) adj ("4" or IV) adj inhibitor?).tw. 13. (alogliptin or SYR 322 or SYR322).tw. 14. anagliptin.tw. 15. bisegliptin.tw. 16. (carmegliptin or R1579 or RO4876904).tw. 17. (denagliptin or GW 823093 or GW823093).tw. 18. (dutogliptin or PHX1149).tw. 19. (evogliptin or DA 1229).tw. 20. (gemigliptin or LC15 0444).tw. 21. (gosogliptin or PF 00734200 or PF 734200).tw. 22. (linagliptin or BI 1356 or BS 1356).tw. 23. (melogliptin or GRC 8200).tw. 24. (omarigliptin or MK 3102).tw. 25. (sitagliptin or MK 0431).tw. 26. (saxagliptin or BMS 477118).tw. 27. (teneligliptin).tw. 28. (trelagliptin or SYR 472).tw. 29. (vildagliptin or LAF 237 or LAF237).tw. 30. exp Glucagon‐Like Peptide 1/aa,ag [Analogs & Derivatives, Agonists] 31. ((glucagon like peptide* or GLP 1 or GLP1) adj3 (analog* or agonist*)).tw. 32. (exenatide or AC 2993 or ITCA 650).tw. 33. (liraglutide or NN 2211 or NN2211 or NNC 90 1170 or NNC90 1170).tw. 34. (albiglutide or GSK 716155).tw. 35. (elsiglutide).tw. 36. (lixisenatide or AVE 0010).tw. 37. (dulaglutide or LY2189265 or LY 2189265).tw. 38. (taspoglutide or BIM 51077 or BIM51077 or ITM 077 or ITM077 or R 1583 or R1583 or RO 5073031 or RO5073031).tw. 39. (semaglutide or NN 9535 or NN9535).tw. 40. (teduglutide or ALX 0600 or ALX0600).tw. 41. or/10‐40 Block 1 AND block 2 AND filters 42. 9 and 41 [43‐53: Cochrane Handbook 2008 RCT filter ‐ sensitivity max. version] 43. randomized controlled trial.pt. 44. controlled clinical trial.pt. 45. randomi?ed.ab. 46. placebo.ab. 47. drug therapy.fs. 48. randomly.ab. 49. trial.ab. 50. groups.ab. 51. or/43‐50 52. exp animals/ not humans/ 53. 51 not 52 54. 42 and 53 [55:Wong 2006a– systematic reviews filter – SensSpec version] 55. meta analysis.mp,pt. or review.pt. or search*.tw. 56. 42 and 55 57. 54 or 56

Embase (OvidSP)

Block 1: Prediabetes 1. impaired glucose tolerance/ 2. (prediabet* or pre diabet*).tw. 3. intermediate hyperglyc?emi*.tw. 4. ((impaired fasting adj2 glucose) or IFG or impaired FPG).tw. 5. glucose intolerance.tw. 6. ((impaired glucose adj (tolerance or metabolism)) or IGT).tw. 7. ((risk or progress* or prevent* or inciden* or conversion or develop* or delay*) adj4 (diabetes or T2D* or NIDDM or "type 2" or "type II")).tw. 8. or/1‐7 Block 2: DPP‐4 inhibitors/GLP‐1 analogues 9. gliptin*.tw. 10. ((dipeptidyl peptidase or dipeptidylpeptidase or dpp) adj ("4" or IV) adj inhibitor?).tw. 11. (alogliptin or SYR 322 or SYR322).tw. 12. anagliptin.tw. 13. bisegliptin.tw. 14. (carmegliptin or R1579 or RO4876904).tw. 15. (denagliptin or GW 823093 or GW823093).tw. 16. (dutogliptin or PHX1149).tw. 17. (evogliptin or DA 1229).tw. 18. (gemigliptin or LC15 0444).tw. 19. (gosogliptin or PF 00734200 or PF 734200).tw. 20. (linagliptin or BI 1356 or BS 1356).tw. 21. (melogliptin or GRC 8200).tw. 22. (omarigliptin or MK 3102).tw. 23. (sitagliptin or MK 0431).tw. 24. (saxagliptin or BMS 477118).tw. 25. (teneligliptin).tw. 26. (trelagliptin or SYR 472).tw. 27. (vildagliptin or LAF 237 or LAF237).tw. 28. ((glucagon like peptide* or GLP 1 or GLP1) adj3 (analog* or agonist*)).tw. 29. (exenatide or AC 2993 or ITCA 650).tw. 30. (liraglutide or NN 2211 or NN2211 or NNC 90 1170 or NNC90 1170).tw. 31. (albiglutide or GSK 716155).tw. 32. (elsiglutide).tw. 33. (lixisenatide or AVE 0010).tw. 34. (dulaglutide or LY2189265 or LY 2189265).tw. 35. (taspoglutide or BIM 51077 or BIM51077 or ITM 077 or ITM077 or R 1583 or R1583 or RO 5073031 or RO5073031).tw. 36. (semaglutide or NN 9535 or NN9535).tw. 37. (teduglutide or ALX 0600 or ALX0600).tw. 38. or/9‐37 Block 1 AND block 2 AND filter 39. 8 and 38 [40:Wong 2006b"sound treatment studies" filter – BS version] 40. random*.tw. or clinical trial*.mp. or exp health care quality/ 41. 39 and 40

PubMed (subsets not available on Ovid)

#1 ((prediabet*[tiab] OR pre diabet*[tiab] OR hyperglyc*[tiab] OR ("impaired fasting"[tiab] AND glucose[tiab]) OR IFG[tiab] OR "impaired FPG"[tiab] OR "glucose intolerance"[tiab] OR ("impaired glucose"[tiab] AND (tolerance[tiab] OR metabolism[tiab])) OR IGT[tiab] OR ((risk[tiab] OR progress*[tiab] OR prevent*[tiab] OR inciden*[tiab] OR conversion[tiab] OR develop*[tiab] OR delay*[tiab]) AND (diabetes[tiab] OR T2D*[tiab] OR NIDDM[tiab] OR "type 2"[tiab] OR "type II"[tiab])))) #2 (gliptin*[tiab] OR "dipeptidyl peptidase 4"[tiab] OR "DPP 4"[tiab] OR DPP4[tiab] OR "dipeptidyl peptidase IV"[tiab] OR "DPP IV"[tiab] OR alogliptin[tiab] OR "SYR 322"[tiab] OR SYR322[tiab] OR anagliptin[tiab] OR bisegliptin[tiab] OR carmegliptin[tiab] OR R1579[tiab] OR RO4876904[tiab] OR denagliptin[tiab] OR "GW 823093"[tiab] OR GW823093[tiab] OR dutogliptin[tiab] OR PHX1149[tiab] OR evogliptin[tiab] OR "DA 1229"[tiab] OR gemigliptin[tiab] OR "LC15 0444"[tiab] OR gosogliptin[tiab] OR "PF 00734200"[tiab] OR "PF 734200"[tiab] OR linagliptin[tiab] OR "BI 1356"[tiab] OR "BS 1356"[tiab] OR melogliptin[tiab] OR "GRC 8200"[tiab] OR omarigliptin[tiab] OR "MK 3102"[tiab] OR sitagliptin[tiab] OR "MK 0431"[tiab] OR saxagliptin[tiab] OR "BMS 477118"[tiab] OR teneligliptin[tiab] OR trelagliptin[tiab] OR "SYR 472"[tiab] OR vildagliptin[tiab] OR "LAF 237"[tiab] OR LAF237[tiab] OR "glucagon like peptide"[tiab] OR "GLP 1"[tiab] OR GLP1[tiab] OR exenatide[tiab] OR "AC 2993"[tiab] OR "ITCA 650"[tiab] OR liraglutide[tiab] OR "NN 2211"[tiab] OR NN2211[tiab] OR "NNC 90 1170"[tiab] OR "NNC90 1170"[tiab] OR albiglutide[tiab] OR "GSK 716155"[tiab] OR elsiglutide[tiab] OR lixisenatide[tiab] OR "AVE 0010"[tiab] OR dulaglutide[tiab] OR LY2189265[tiab] OR "LY 2189265"[tiab] OR taspoglutide[tiab] OR "BIM 51077"[tiab] OR BIM51077[tiab] OR "ITM 077"[tiab] OR ITM077[tiab] OR "R 1583"[tiab] OR R1583[tiab] OR "RO 5073031"[tiab] OR RO5073031[tiab] OR semaglutide[tiab] OR "NN 9535"[tiab] OR NN9535[tiab] OR teduglutide[tiab] OR "ALX 0600"[tiab] OR ALX0600[tiab]) #3 #1 AND #2 #4 publisher[sb] #5 #3 AND #4 #6 (random*[tiab] OR placebo[tiab] OR trial[tiab] OR groups[tiab]) OR (meta analysis[tiab] OR review[tiab] OR search*[tiab]) #7 #5 AND #6

ClinicalTrials.gov (Expert search)

(prediabetes OR prediabetic OR "pre diabetes" OR "pre diabetic" OR hyperglycemia OR hyperglycaemia OR hyperglycemic OR hyperglycaemic OR "impaired glucose tolerance" OR "impaired fasting glucose" OR "glucose intolerance" OR IGT OR IFG OR ((diabetes OR "type 2" OR "type II" OR T2D OR T2DM) AND (risk OR progress OR progression OR progressed OR incident OR incidence OR conversion OR developed OR development OR develop OR delay OR delayed OR prevention OR prevent OR prevented))) AND (gliptin OR "dipeptidyl peptidase 4" OR "DPP 4" OR DPP4 OR "dipeptidyl peptidase IV" OR "DPP IV" OR alogliptin OR "SYR 322" OR SYR322 OR anagliptin OR bisegliptin OR carmegliptin OR R1579 OR RO4876904 OR denagliptin OR "GW 823093" OR GW823093 OR dutogliptin OR PHX1149 OR evogliptin OR "DA 1229" OR gemigliptin OR "LC15 0444" OR gosogliptin OR "PF 00734200" OR "PF 734200" OR linagliptin OR "BI 1356" OR "BS 1356" OR melogliptin OR "GRC 8200" OR omarigliptin OR "MK 3102" OR sitagliptin OR "MK 0431" OR saxagliptin OR "BMS 477118" OR teneligliptin OR trelagliptin OR "SYR 472" OR vildagliptin OR "LAF 237" OR LAF237 OR "glucagon like peptide" OR "GLP 1" OR GLP1 OR exenatide OR "AC 2993" OR "ITCA 650" OR liraglutide OR "NN 2211" OR NN2211 OR "NNC 90 1170" OR "NNC90 1170" OR albiglutide OR "GSK 716155" OR elsiglutide OR lixisenatide OR "AVE 0010" OR dulaglutide OR LY2189265 OR "LY 2189265" OR taspoglutide OR "BIM 51077" OR BIM51077 OR "ITM 077" OR ITM077 OR "R 1583" OR R1583 OR "RO 5073031" OR RO5073031 OR semaglutide OR "NN 9535" OR NN9535 OR teduglutide OR "ALX 0600" OR ALX0600) AND INFLECT EXACT "Interventional" [STUDY‐TYPES]

ICTRP Search Portal (Standard search)

[string to be run in six parts] 1. prediabetes AND alogliptin OR pre diabetes AND alogliptin OR impaired glucose tolerance AND alogliptin OR impaired fasting glucose AND alogliptin OR glucose intolerance AND alogliptin OR diabetes AND risk AND alogliptin OR diabetes AND prevent* AND alogliptin OR prediabetes AND anagliptin OR pre diabetes AND anagliptin OR impaired glucose tolerance AND anagliptin OR impaired fasting glucose AND anagliptin OR glucose intolerance AND anagliptin OR diabetes AND risk AND anagliptin OR diabetes AND prevent* AND anagliptin OR prediabetes AND bisegliptin OR pre diabetes AND bisegliptin OR impaired glucose tolerance AND bisegliptin OR impaired fasting glucose AND bisegliptin OR glucose intolerance AND bisegliptin OR diabetes AND risk AND bisegliptin OR diabetes AND prevent* AND bisegliptin OR prediabetes AND carmegliptin OR pre diabetes AND carmegliptin OR impaired glucose tolerance AND carmegliptin OR impaired fasting glucose AND carmegliptin OR glucose intolerance AND carmegliptin OR diabetes AND risk AND carmegliptin OR diabetes AND prevent* AND carmegliptin OR prediabetes AND denagliptin OR pre diabetes AND denagliptin OR impaired glucose tolerance AND denagliptin OR impaired fasting glucose AND denagliptin OR glucose intolerance AND denagliptin OR diabetes AND risk AND denagliptin OR diabetes AND prevent* AND denagliptin 2. prediabetes AND dutogliptin OR pre diabetes AND dutogliptin OR impaired glucose tolerance AND dutogliptin OR impaired fasting glucose AND dutogliptin OR glucose intolerance AND dutogliptin OR diabetes AND risk AND dutogliptin OR diabetes AND prevent* AND dutogliptin OR prediabetes AND evogliptin OR pre diabetes AND evogliptin OR impaired glucose tolerance AND evogliptin OR impaired fasting glucose AND evogliptin OR glucose intolerance AND evogliptin OR diabetes AND risk AND evogliptin OR diabetes AND prevent* AND evogliptin OR prediabetes AND gemigliptin OR pre diabetes AND gemigliptin OR impaired glucose tolerance AND gemigliptin OR impaired fasting glucose AND gemigliptin OR glucose intolerance AND gemigliptin OR diabetes AND risk AND gemigliptin OR diabetes AND prevent* AND gemigliptin OR prediabetes AND gosogliptin OR pre diabetes AND gosogliptin OR impaired glucose tolerance AND gosogliptin OR impaired fasting glucose AND gosogliptin OR glucose intolerance AND gosogliptin OR diabetes AND risk AND gosogliptin OR diabetes AND prevent* AND gosogliptin OR prediabetes AND linagliptin OR pre diabetes AND linagliptin OR impaired glucose tolerance AND linagliptin OR impaired fasting glucose AND linagliptin OR glucose intolerance AND linagliptin OR diabetes AND risk AND linagliptin OR diabetes AND prevent* AND linagliptin 3. prediabetes AND melogliptin OR pre diabetes AND melogliptin OR impaired glucose tolerance AND melogliptin OR impaired fasting glucose AND melogliptin OR glucose intolerance AND melogliptin OR diabetes AND risk AND melogliptin OR diabetes AND prevent* AND melogliptin OR prediabetes AND omarigliptin OR pre diabetes AND omarigliptin OR impaired glucose tolerance AND omarigliptin OR impaired fasting glucose AND omarigliptin OR glucose intolerance AND omarigliptin OR diabetes AND risk AND omarigliptin OR diabetes AND prevent* AND omarigliptin OR prediabetes AND sitagliptin OR pre diabetes AND sitagliptin OR impaired glucose tolerance AND sitagliptin OR impaired fasting glucose AND sitagliptin OR glucose intolerance AND sitagliptin OR diabetes AND risk AND sitagliptin OR diabetes AND prevent* AND sitagliptin OR prediabetes AND saxagliptin OR pre diabetes AND saxagliptin OR impaired glucose tolerance AND saxagliptin OR impaired fasting glucose AND saxagliptin OR glucose intolerance AND saxagliptin OR diabetes AND risk AND saxagliptin OR diabetes AND prevent* AND saxagliptin OR prediabetes AND teneligliptin OR pre diabetes AND teneligliptin OR impaired glucose tolerance AND teneligliptin OR impaired fasting glucose AND teneligliptin OR glucose intolerance AND teneligliptin OR diabetes AND risk AND teneligliptin OR diabetes AND prevent* AND teneligliptin 4. prediabetes AND trelagliptin OR pre diabetes AND trelagliptin OR impaired glucose tolerance AND trelagliptin OR impaired fasting glucose AND trelagliptin OR glucose intolerance AND trelagliptin OR diabetes AND risk AND trelagliptin OR diabetes AND prevent* AND trelagliptin OR prediabetes AND vildagliptin OR pre diabetes AND vildagliptin OR impaired glucose tolerance AND vildagliptin OR impaired fasting glucose AND vildagliptin OR glucose intolerance AND vildagliptin OR diabetes AND risk AND vildagliptin OR diabetes AND prevent* AND vildagliptin OR prediabetes AND GLP OR pre diabetes AND GLP OR impaired glucose tolerance AND GLP OR impaired fasting glucose AND GLP OR glucose intolerance AND GLP OR diabetes AND risk AND GLP OR diabetes AND prevent* AND GLP OR prediabetes AND exenatide OR pre diabetes AND exenatide OR impaired glucose tolerance AND exenatide OR impaired fasting glucose AND exenatide OR glucose intolerance AND exenatide OR diabetes AND risk AND exenatide OR diabetes AND prevent* AND exenatide OR prediabetes AND liraglutide OR pre diabetes AND liraglutide OR impaired glucose tolerance AND liraglutide OR impaired fasting glucose AND liraglutide OR glucose intolerance AND liraglutide OR diabetes AND risk AND liraglutide OR diabetes AND prevent* AND liraglutide 5. prediabetes AND albiglutide OR pre diabetes AND albiglutide OR impaired glucose tolerance AND albiglutide OR impaired fasting glucose AND albiglutide OR glucose intolerance AND albiglutide OR diabetes AND risk AND albiglutide OR diabetes AND prevent* AND albiglutide OR prediabetes AND elsiglutide OR pre diabetes AND elsiglutide OR impaired glucose tolerance AND elsiglutide OR impaired fasting glucose AND elsiglutide OR glucose intolerance AND elsiglutide OR diabetes AND risk AND elsiglutide OR diabetes AND prevent* AND elsiglutide OR prediabetes AND lixisenatide OR pre diabetes AND lixisenatide OR impaired glucose tolerance AND lixisenatide OR impaired fasting glucose AND lixisenatide OR glucose intolerance AND lixisenatide OR diabetes AND risk AND lixisenatide OR diabetes AND prevent* AND lixisenatide OR prediabetes AND dulaglutide OR pre diabetes AND dulaglutide OR impaired glucose tolerance AND dulaglutide OR impaired fasting glucose AND dulaglutide OR glucose intolerance AND dulaglutide OR diabetes AND risk AND dulaglutide OR diabetes AND prevent* AND dulaglutide OR prediabetes AND taspoglutide OR pre diabetes AND taspoglutide OR impaired glucose tolerance AND taspoglutide OR impaired fasting glucose AND taspoglutide OR glucose intolerance AND taspoglutide OR diabetes AND risk AND taspoglutide OR diabetes AND prevent* AND taspoglutide 6. prediabetes AND semaglutide OR pre diabetes AND semaglutide OR impaired glucose tolerance AND semaglutide OR impaired fasting glucose AND semaglutide OR glucose intolerance AND semaglutide OR diabetes AND risk AND semaglutide OR diabetes AND prevent* AND semaglutide OR prediabetes AND teduglutide OR pre diabetes AND teduglutide OR impaired glucose tolerance AND teduglutide OR impaired fasting glucose AND teduglutide OR glucose intolerance AND teduglutide OR diabetes AND risk AND teduglutide OR diabetes AND prevent* AND teduglutide